We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Novel Polymer Reduces Bone Bleeding Surgical Infection Risk

By HospiMedica staff writers
Posted on 25 Feb 2008
An innovative polymer material designed to stop bone bleeding during surgery decreases the risk of surgical infection when the bone is exposed to bacteria such as methicillin-resistant Staphylococcus aureus (MRSA).

In an animal study, researchers from the Medical University of South Carolina (MUSC, Charleston, USA) and the University of Southern California (USC, Los Angeles, USA) compared a newly available polymer called Ostene to bone wax, traditionally used to stop bone bleeding in surgically cut bone surfaces. More...
The scientists looked at the two materials' effect on bone infection in the presence of S. aureus. The results showed that only a quarter of the bones treated with Ostene were infected, unlike the bones treated with bone wax, all of which developed an infection. The study also showed that the bones treated with Ostene healed normally, while the presence of bone wax inhibited bone growth. The researchers suggest that the use of Ostene may have implications for reducing the risk of surgical site infection and for improving post-operative healing and recovery. The study was published in the February 2008 issue of Clinical Orthopaedics and Related Research.

Ostene, a product of Ceremed (Los Angeles, USA), is a sterile mixture of water-soluble alkylene oxide copolymers that form a synthetic bone hemostasis material that reduces the overall risk of post surgical infections, sternal non-union, poor bone healing, and chronic inflammation. Ostene is wax-like and malleable during application, dissolves rapidly, and is eliminated from the body shortly after surgery. The material's main polymer component inherently reduces bacterial adhesion.

"Ostene's unique properties are particularly significant now that we are battling the threat of hospital-acquired infections, especially MRSA,” said Tadeusz Wellisz, M.D., President and CEO of Ceremed. "Ceremed is currently developing the next generation of Ostene with antibiotics, specifically designed to prevent hospital-acquired surgical infection.”


Related Links:
Medical University of South Carolina
University of Southern California
Ceremed

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.